Immunovant shares surge after antibody treatment succeeds in early-stage study
Sept 26 (Reuters) – Shares of Immunovant (IMVT.O) more than doubled on Tuesday after early-stage data from its experimental antibody treatment exceeded analysts’ expectations.The drug developer, whose shares hit a more than two-and-a-half year high of $41.72, was set to add nearly $3 billion to its market capitalization if gains hold.Immunovant is developing its antibody… […]